Background: Glycyrrhizic acid (GA) was found to improve blood glucose and dyslipidaemia with increased lipoprotein lipase (LPL) expression and reduction in 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1), hexose-6-phosphate dehydrogenase (H6PDH), phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) activities in liver, kidney, skeletal muscles and adipose tissues. However, it was not known if these were a direct action from GA or indirect involving glucocorticoids (GC). Methods: Adrenalectomised (ADX) rats were used to investigate the effects of GA administration on glucose and lipid metabolism in the absence of endogenous GC. Thirty male Sparague Dawley rats were randomly assigned to three groups of ten; designated the sham, ADX and GA-administered (100mg/kg; orally) ADX groups. After 28 days of treatment, the blood samples collected were analysed for glucose, serum insulin and lipid profiles. Tissues collected were analysed for LPL expression and 11β-HSD1, H6PDH, PEPCK and G6 Pase activities. Result: Improvement in blood glucose level was seen in ADX compared to the sham rats (33%; p<0.05) but no difference in GA-administered ADX rats (p>0.05). Adrenalectomy also led to significant reduction in PEPCK (p<0.05) and G6Pase (p<0.05) activities in the liver and kidney. GA administration to ADX rats showed elevation of PEPCK activities in adipose tissues (p<0.05). Reduction in 11β-HSD1 (p>0.05) and H6PDH (p<0.05) activities were seen in all the tissues of ADX rats and GA administration further reduced these activities (p>0.05). Improvement in cholesterol levels (p<0.05) was seen in GA-administered ADX rats with increase liver LPL expression (p<0.05). Conclusion: Reduction of hepatic and renal PEPCK, G6Pase and H6PDH activities by GA could be due to inhibition of 11β-HSD1 involving GC. However, increased PEPCK activities in adipose tissues, reduction in H6PDH activities in all the aforementioned tissues and improvement of LPL expression appeared to be independent of GC..
INTRODUCTION
Metabolic syndrome (MetS) is a metabolic disorder characterised by the co-existence of hyperglycaemia, dyslipidaemia, hypertension and abdominal obesity with insulin resistance (IR) as the central component [1] . It has become a recognisable cluster of clinical risk factors that are predictive of the progression to cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) [2] .
Dysfunctions of the adrenal gland have been associated with multiple consequences in carbohydrate, fat and protein metabolism. Imbalances in the adrenal hormones have been greatly associated with the development of obesity and obesity-related illnesses or metabolic syndromes [3] . The striking communalities between obesity (especially abdominal) and syndromes where hypercortisolism is a common feature (such as Cushing and Cushing-like syndrome) have led to underscore the role of glucocorticoids (GCs) in the pathophysiology of human obesity. GCs are the counter-regulatory hormones known to modulate glycogen synthesis and gluconeogenesis by increasing glycogen synthase and gluconeogenic enzymes and also by increasing the release of amino acids from the muscle for use as gluconeogenic substrates [4] . Hence, by correcting imbalances in these hormones, development of MetS could be ameliorated.
Various studies have shown that with the development of IR, the production and activity of the enzyme lipoprotein lipase (LPL) is reduced [5] . LPL plays an essential role in lipid metabolism by hydrolysing the circulating triglycerides (TAG) of TAG-rich lipoprotein, namely chylomicrons and very-low density lipoprotein (VLDL) to free fatty acids (FFA) in addition to playing a central role in overall lipoprotein metabolism. LPL is regulated by the upstream peroxisome proliferator activator receptor (PPAR) [6] . Reduced LPL activity has been shown to lead to a reduction in the lipolytic rate of the chylomicrons and the very-low-density lipoproteins (VLDL). This results in gradual development of hypertriglyceridaemia and subsequently dyslipidaemia. Thus, tissue specific regulation of LPL is essential for proper fuel partitioning, body weight regulation and insulin action [7] .
Overexpression of hexose-6-phosphate dehydrogenase (H6PDH), phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) were also observed in T2DM patients when GCs were found to be in excess [8] [9] . H6PDH catalyses the first two steps of the pentose phosphate pathway within the endoplasmic reticulum (ER) lumen. It has a bifunctional activity where H6PDH oxidizes glucose-6-phosphate (G6P) to 6-phosphogluconolactone (6PGL) and concomitantly generates reduced nicotinamide adenine dinucleotide phosphate (NADPH) from NADP + [10] [11] . The conversion of inactive GCs to active GCs is catalysed by 11β-hydroxysteroid dehydrogenase (11β-HSD1), which utilizes NADPH generated from H6PDH [12] . Thus, the reductase activity of 11β-HSD1 is strongly dependent on the availability of NADPH, which further relies on G6P availability within the ER lumen [10] . PEPCK and G6Pase are the critical enzymes in metabolism as both of these are involved in the rate-limiting step of both gluconeogenesis and glyceroneogenesis [13] . PEPCK simultaneously decarboxylates and phosphorylates oxaloacetic acid into phosphoenolpyruvate while G6Pase hydrolyses G6P into glucose [14] .
Excess production of GCs leads to diet-or stressinduced obesity via excess energy intake [15] while catecholamines are mainly associated with energy expenditure in obesity [16] . Hence, removal of GCs by adrenalectomy may therefore lead to a reduction in liver gluconeogenesis [17] and liver glycogen deposition [18] characteristic of obese mice and be responsible, at least in part, for the hypoglycaemia that accompanies adrenalectomy. In addition, adrenalectomy reduces food intake [19] , slows body weight gain [20] , increases energy expenditure due to enhanced thermogenesis in brown adipose tissues [21] as well as restores noradrenaline turnover to normal in brown adipose tissue and heart in genetically obese (fa/fa) rats [22] .
Glycyrrhizic acid (GA), a triterpenoid compound, is the main bioactive compound found in the roots of the shrub Glycyrrhiza glabra. Studies have shown that oral administration of 100 mg/kg of GA to high-fat diet induced obese rats for 28 days led to significant improvement in insulin sensitivity, together with an apparent hypotriglyceridaemic, HDL-raising effects as well as the up-regulation of LPL expression mainly in oxidative tissues and reduction in tissue lipid deposition [23] . GA also up-regulate tissues total PPAR-γ and LPL expression levels in the liver, kidney, abdominal and quadriceps femoris muscles, and visceral and subcutaneous adipose tissue [24] . As mentioned earlier, elevated GC level is a feature of MetS and elevated GC subsequently induces hyperglycaemia by stimulating the gluconeogenic enzymes PEPCK and G6Pase [9] . Reduction in tissue PEPCK, G6Pase and H6PDH activities following the oral administration of GA on rats had also been observed (Wong SMA, unpublished observations). This was postulated to be due to the decreased GC concentration resulting from GA action. To date however, the possibility of GA acting via an alternative pathway in addition to inhibiting 11β-HSD1 in the amelioration of MetS has yet to be conducted. It is not known if the elevation of tissue LPL expression or the tissue PEPCK, G6Pase and H6PDH activities are the direct effect of GA or indirect effect involving the GC. To answer the question, adrenalectomised (ADX) rats were used in the present study. Without endogenous steroids, any effect of GA will be a direct action on LPL expression or PEPCK, G6Pase and H6PDH activities. The objectives of this study are therefore to investigate the effects of GA on glucose and lipid metabolism in the absence of endogenous steroids. This was done by determining the insulin sensitivity, lipid parameters, LPL expression and lipid deposition, as well as the aforementioned enzyme activities in GAadministered ADX rats.
MATERIALS AND METHODS

Animals and treatment
The use and handling procedure of animals in this research project had been approved by the Monash University School of Biomedical Sciences Animal Ethics Committee (AEC Approval Number: SOBSB/MY/2010/01). 30 male Sprague Dawley rats (Rattus novergicus) weighing between 190-210 g were obtained from the Animal House of Monash University Sunway Campus and were housed individually in polypropylene cages in a room kept at 23°C on a 12-hour light and dark cycle (lights on at 0600 hours and lights out at 1800 hours). The rats were randomly assigned to three groups of ten; designated the sham, adrenalectomised and GA-administered adrenalectomised groups. Bilateral adrenalectomy (n=20) or sham operation (n=10) were performed under light ether anaesthesia. 2 mg/kg Meloxicam (Boehringer Ingelheim, Australia) was injected subcutaneously around the incision area prior to the incision. All the rats underwent 12 days of post-surgery recovering period prior to the start of the experiment. Betadine® solution (Mahakam Beta Farma, Indonesia) was applied to the wounds and the cages were cleaned and bedding was changed every day. All the rats were given standard rat chow (Gold Coin, Malaysia) and 0.9% saline for their drinking water in order to replace the acute sodium loss in ADX animals upon adrenalectomy, thus delaying or preventing the appearance of adrenalectomy-induced alterations that might lead to any lethal effect [34] . The sham group was also given saline to ensure that the only variables existing in the study is the lack of adrenal glands and the GA-administration.
Stitches were removed at the 10th day. During the treatment period, rats in both the sham and the adrenalectomised groups were given 0.9% saline while GA-administered adrenalectomised groups were administered orally with 100 mg/kg GA in 0.9% saline daily. The treatment for all were 28 days and the amount of food and saline or GA consumed was recorded daily.
Systolic blood pressure measurement
Systolic blood pressure was measured using the NIBP controller (ADInstruments, Australia). Conscious rats were placed into a plastic restrainers of which the length was adjusted to fit the animal comfortably but restricting their movements. A tail-cuff with a pulse transducer was applied onto the tail of the restrained animal and the tail was heated for 20-30 minutes using a table lamp with 60W bulb to facilitate the dilation of caudal arteries. Blood pressure was measured by inflating the tail-cuff once the heart rate had stabilised. The recording and determination of systolic blood pressure were performed using the Chart recording software. This procedure was performed once a week on all the rats throughout the 28 days.
Blood and tissue sampling
Upon completion of the treatment period, the rats were fasted for 12 hours prior to humane sacrifice between 0800 to 1000 hours under the influence of pentobarbital sodium (Nembutal) anaesthesia (150 mg/kg body wt. IP). Blood was drawn from the cardiac ventricle via the apex of the heart using a 5 ml syringe with 22G needle. Five drops of blood were added into a microcentrifuge tube containing 0.5g of ethylenediamine tetraacetic acid (EDTA) and sodium fluoride (NaF) (1:2 w/w). The contents were then mixed thoroughly prior to the determination of plasma glucose levels. The remaining blood was collected into a sterile Falcon tube and allowed to clot at room temperature (25°C) for 30 minutes prior to centrifugation at 12,000 × g for 10 minutes at 4°C. The resulting serum was then rapidly transferred into microcentrifuge tubes and stored at -80°C until required for analysis. The seven tissues of interest: liver, kidney, heart, abdominal muscle (AM), quadriceps femoris (QF) and visceral (VAT) and subcutaneous adipose tissues (SAT) were promptly harvested. For PEPCK activity, the liver, kidney, SAT and VAT tissues were immersed in Tris-HCl buffer, pH 7.4 at 4°C. For H6PDH and G6Pase activities, the liver, kidney, SAT and VAT, AM and QF tissues were immersed in HEPES-KOH buffer (pH 7.2), at 4°C. For 11β-HSD activity, liver, kidney, SAT and VAT, AM and QF tissues were immersed in Krebs-Ringer bicarbonate (KRB) buffer (pH 7.4) at 4°C. The remaining fractions from the above and other tissues were placed into individual cryovials (Nalgene, USA) and immediately snap-frozen in liquid nitrogen. These latter fractions were then stored at -80°C until required for analysis. In addition to that, a fraction of the VAT and SAT were immersed in 10% neutral-buffered formalin in individual universal bottles for histological analysis.
The tissues which were collected and immersed in TRIS-HCl (pH 7.4) for PEPCK, HEPES-KOH buffer (pH 7.2) for H6PDH and G6pase and KRB buffer for 11β-HSD were subsequently homogenized and centrifuged. For the PEPCK, the supernatant containing the cytosolic fraction was stored at -70°C with glycerol. For the H6PDH and G6Pase, the pellet was resuspended in MOPS buffer and the suspension was kept at -70°C with glycerol until required for analysis. For the 11β-HSD, substrate mixture (0.1mM substrate containing corticosterone, 0.35mM NADP + , 0.2% BSA, 0.2% glucose and 5% ethanol) was added to the supernatant and incubated for an hour at 37°C. The reaction tubes were later stored at -20°C until required for analysis.
Protein determination
The protein contents of the collected samples were determined using the modified Lowry's method (BioRad DC Protein assay) before the determination of enzyme activities [28] .
Determination of phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase) and hexose-6-phosphate dehydrogenase (H6PDH) activities PEPCK activities in the liver, kidney, SAT and VAT were determined based on the coupled reaction between the PEPCK and malate dehydrogenase as described by Petrescu et al. [25] . One unit of PEPCK activity was expressed as nanomoles of NADH oxidized per minute per milligram protein (nmoles NADH oxidized/min/mg protein). Determination of G6pase activities in the liver and kidney tissues were performed based on the hydrolysis of glucose-6-phosphate to inorganic phosphate by measuring the amount of phosphate formed in the media over a period of three minutes [26] . One unit of G6Pase activity was expressed as nanomoles of inorganic phosphate formed per minute per milligram of protein (nmoles P formed/min/mg protein) over a period of three minutes. Apart from that, H6PDH activities in the liver, kidney, SAT, VAT, AM and QF tissues were determined by measuring the amount of NADPH generated in the media over a period of five minutes [27] . One unit of H6PDH activity was expressed in nanomoles of NADPH generated per minute per milligram protein (nmoles NADH generated/min/mg protein).
Determination of 11β-hydroxysteroid dehydrogenase type-1 (11β-HSD1) activities 11β-HSD1 activities were determined by using reversephase high performance liquid chromatography (HPLC) as described by Chandramouli et al. [28] , via the quantification of GC, 11-dehydrocorticosterone, which is the product of the dehydrogenation of the substrate, corticosterone. One unit of 11β-HSD1 activity was expressed as one picomole of 11-dehydrocorticosterone produced/50mg of tissue protein used/hour.
Blood biochemical analysis
Blood glucose was determined using the Trinder's glucose oxidase method while serum insulin was determined using the Rat/Mouse Insulin ELISA kit (Millipore, USA). The insulin sensitivity of each rat was determined using Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) indices, which involved the product of fasting plasma glucose and fasting serum insulin in mmol/L and mg/ml respectively divided by 22.5 [29] . Serum TAG, FFA and total cholesterol were determined using Randox TR1697 Triglycerides kit (Randox, UK), Randox FA115 Non-Esterified Fatty Acids kit (Randox, UK) and Randox CH200 Cholesterol kit (Randox, UK) respectively. HDL-cholesterol was determined using the aforementioned cholesterol kit after precipitation of HDL using the Randox CH203 HDL Precipitant kit (Randox, UK). LDL-cholesterol was calculated using the Friedewald formula, using the levels of total cholesterol, TAG and HDL cholesterol obtained [30] .
Real-time reverse transcription polymerase chain reaction (qRT-PCR) of LPL gene
Total RNA from the liver, kidney, AM and QF was isolated using Qiagen RNeasy Mini kit (Qiagen, USA) while the total RNA from the SAT and VAT was isolated using Qiagen RNeasy Lipid Tissue Mini kit (Qiagen, USA). The purity of the RNA was determined by measuring absorbance at 260 nm and 280 nm (A 260 /A 280 ratio) where a ratio of 1.9-2.1 is considered pure. RNase-free DNase treatment was performed using Promega RQ1 RNase-free DNase (Promega, USA) and cDNA synthesis was performed using the Qiagen Omniscript Reverse Transcriptase kit (Qiagen, USA). Relative LPL expression was determined by qRT-PCR using the Comparative Ct Amplicons generated from qRT-PCR was run on agarose gel electrophoresis to ensure primer specificity.
Tissue lipid staining
Frozen tissues were cut into small cubes of approximately 5 × 5 × 5 mm on sterile petri dishes and fixed onto a cryotome mould using the Optimal Cutting Temperature (OCT) Compound (Leica, Germany). The tissues were allowed to freeze within the compound, after which the embedded tissues were sectioned into 5 μm slices and adhered onto glass slides. Cryosectioning was performed using the Thermo Shandon Cryotome (Thermo Scientific, UK) at a temperature of -25°C. Staining was performed in accordance to Koopman et al. [31] and captured at 200X magnification. Lipid deposition was quantified as specified by Goodpaster et al. [32] . Briefly, captured images were transferred to Image J software and converted to greyscale. Threshold for the intensity of staining was adjusted in order to pick up only the droplets of lipid. Pixels with intensities of 150 ± 30 arbitrary unit (AU) were quantified (the full-range being from 0-255 (AU), where 0 represents complete staining and 255 represents no staining). The mean of eight values from eight contiguous views captured was used to determine the level of lipid deposition in arbitrary units (AU).
Determination of size of adipocytes
Morphometric analysis of adipocytes was performed in accordance to Lim et al. [33] . Adipose tissues that were fixed in 10% neutral-buffered formalin as aforementioned were processed by a Leica TP 1020 Automatic Tissue Processor and embedded in paraffin. 5 μm thick tissue sections were then stained with haematoxylin and eosin (H&E) followed by the measurement of the size of 25 adipocytes (μm 2 ) per field view per tissue section at 100× magnification.
Statistical analysis
Statistical analysis for LPL expression was performed using the Relative Expression Software Tool (REST © ) MCS Beta 2006. All other data were analysed using Statistical Package for the Social Sciences (SPSS) Version 16.0. Data distribution was analysed using the Kolmogorov-Smirnov test. Data with parametric distribution were analysed using Analysis of Variance (ANOVA) and if the results were significant, Post Hoc (Scheffe) test was performed while non-parametric data were analysed using Kruskall-Wallis test. In all analyses, a p-value ≤ 0.05 was considered statistically significant.
RESULTS
Administration of GA did not induce an increase in systolic blood pressure
Systolic blood pressure of the sham, ADX and the GAadministered ADX groups were compared on week one, two, three and four of the treatment period. No significant difference (p > 0.05) in mean systolic blood pressure was observed between the groups from week one to week four ( Figure 1 ). The mean blood pressure of the sham, ADX, GA-administered ADX groups in week one was 106. 24 ± 2.90, 105.03 ± 2.50 and 99.06 ± 2.40 mmHg respectively. In week two, the mean blood pressure was 102.5 ± 2.34, 102.59 ± 3.06 and 97.96 ± 3.03 mmHg for the sham, ADX and GAadministered ADX groups respectively and it was 98.36 ± 3.54 mmHg, 99.62 ± 3.32 mmHg and 97.11 ± 3.11 mmHg respectively in week three. In week four, the mean blood pressure for the sham group was 103.39 ± 4.27 mmHg, and the ADX and GA-administered ADX groups were 94.46 ± 4.15 and 91.65 ± 1.95 mmHg respectively. Comparing between week one and week four, the mean blood pressure was relatively constant for the sham group (p > 0.05). However, there was a significant decrease (10.1%) in the ADX group between week one (105.03 ± 2.50 mmHg) to week four (94.46 ± 4.15 mmHg) (p < 0.05). A significant decrease (7.5%) was also observed in the GA-administered ADX group in week four (91.65 ± 1.95 mmHg) compared to week one (99.06 ± 2.40 mmHg) (p < 0.05). Adrenalectomy led to a significant decrease (33.0%) in blood glucose (comparing the ADX to the sham groups) (p < 0.05) while no significant difference was observed in the adrenalectomised rats given GA (p > 0.05). Mean serum insulin concentrations were 1.55 ± 0.25 ng/mL, 1.70 ± 0.39 ng/mL and 1.64 ± 0.33 ng/mL for the sham, ADX and GA-administered ADX groups respectively, with no significant difference between the groups (p > 0.05) ( Figure 3 ). The HOMA-IR values were the highest in the sham group (1.20 ± 0.26), followed by the GA-administered ADX (1.15 ± 0.29) and ADX groups (0.98 ± 0.31). Lower HOMA-IR, indicating higher insulin sensitivity, was seen in the ADX group compared to the sham and GA-administered ADX groups. However, the differences between these groups were not significant (p > 0.05) (Figure 4) . Adrenalectomy decreased hepatic and renal PEPCK activities in rats and administration of GA to adrenalectomised rats increased PEPCK activities in adipose tissues
The hepatic PEPCK activities of the sham, ADX and GA-administered ADX groups were 4.04 ± 0.28, 2.46 ± 0.17 and 2.25 ± 0.14 units respectively. The ADX group showed a significant reduction of 39.11% compared to the sham group (p < 0.05). However, the reduction of renal PEPCK was not significant when 100 mg/kg of GA was administered to the GAadministered ADX group (p > 0.05). Renal PEPCK activities were 5.94 ± 0.16, 3.74 ± 0.28 and 3.34 ± 0.25 units in the sham, ADX and GA-administered ADX groups respectively. A significant reduction of 37.04% (p < 0.05) was observed between the ADX and the sham groups while no significant difference was observed in the GA-administered group compared to the ADX group. In SAT, the activities in the sham, ADX, and GA-administered ADX groups were 3.40 ± 0.52, 3.85 ± 0.27 and 4.79 ± 0.25 units respectively. A significant increase of 24.74% (p < 0.05) was observed between the GA-administered ADX and the ADX groups while a no significant difference was seen between the ADX and the sham groups. In the VAT of the sham, ADX and GA-administered ADX groups, the activities were 3.92 ± 0.23, 3.91 ± 0.18 and 4.73 ± 0.30 units respectively. No significant difference was observed between the sham and the ADX groups. However, a significant increase of 20.97% (p < 0.05) was observed between the GA-administered ADX and the ADX groups ( Figure 5 ). 
Administration of GA did not further reduce hepatic and renal G6Pase activities in adrenalectomised rats
Significant reduction in hepatic and renal G6Pase activities was observed in the ADX group compared to the sham group (p < 0.05). However, oral administration of 100 mg/kg GA showed no significant changes in either the hepatic or the renal G6Pase activities (p > 0.05) ( Figure 6 ). Adrenalectomised rats given 100 mg/kg Glycyrrhizic acid orally]
In the liver, the activities were 209. Reduction in Hexose-6-Phosphate dehydrogenase (H6PDH) activities in all tissues were observed in the adrenalectomised rats given GA Overall, significant reduction was observed in the H6PDH activities in the liver, kidney, adipose tissues and abdominal and quadriceps femoris muscles in the ADX group compared to the sham group (p < 0.05).
Further, significant reduction of H6PDH activities in the liver, kidney, abdominal and quadriceps femoris muscles was also observed in the ADX rats given 100 mg/kg GA (p < 0.05) ( Table 1) . For the hepatic H6PDH activities, there was a significant decrease of 40.86% (p < 0.05) in the ADX group compared to the sham group and a significant decrease of 40.15% (p < 0.05) between the GA-administered ADX and the ADX groups. In the kidney, a significant decrease of 19.99% (p < 0.05) was seen in the ADX group compared to the sham group and a significant decrease of 21.19% (p < 0.05) between the GA-administered ADX and the ADX groups. In the SAT, a significant decrease of 14.29% (p < 0.05) was seen between the ADX and the sham groups but no significant difference (p > 0.05) was observed between the GA-administered ADX and the ADX groups. The ADX group had a significant reduction of 14.77% (p < 0.05) in the VAT H6PDH activities compared to the sham group but no significant difference (p > 0.05) was seen between the GA-administered ADX and the ADX groups. In the AM, there was a significant decrease of 22.65% (p < 0.05) between the H6PDH activities of the ADX and the sham groups and a significant decrease of 23.96% (p < 0.05) between the GA-administered ADX and the ADX group. In the H6DPH activities of the QF, a significant decrease of 18.82% (p < 0.05) between the ADX and the sham groups and a significant reduction of 29.33% (p < 0.05) was also observed between the GA-administered ADX and the ADX groups.
Adrenalectomy and GA administration reduced tissues 11β-HSD1 activities
Overall, adrenalectomy (comparing between the ADX and sham groups) led to non-significant difference (p > 0.05) in tissues 11β-HSD1 activities. Non-significant difference (p > 0.05) in 11β-HSD1 activities was further seen with the administration of GA in all the tissues studied except in the QF where significant reduction was seen (p < 0.05) ( Table 1) . Highest activities were seen in the liver compared to all the other tissues. In the liver, a significant reduction of 38.24% was seen between the GA-administered ADX and sham groups (p < 0.05). In the kidney, no significant difference was seen between all the groups (p > 0.05). Non-significant difference had also been observed in the SAT between all the groups (p > 0.05). However in the VAT, a significant reduction of 29.31% (p < 0.05) was seen between the GA-administered ADX and sham groups. Non-significant reductions (p > 0.05) were seen between the ADX and sham groups and between the ADX and GA-administered ADX groups. In the AM, non-significant difference was seen between the ADX and the sham and GA-administered ADX groups (p > 0.05). However, a significant decrease of 26.72% (p < 0.05) was seen between the GA-administered ADX and sham groups. The activity in QF had also been found to be not significant between the ADX and sham groups (p > 0.05). However, significant reductions of 30.47% and 30.98% (p < 0.05) in 11β-HSD1 activities in the QF were seen in the GA-administered ADX compared to the ADX and the sham groups respectively.
Administration of GA improved lipid profiles of adrenalectomised rats
No significant differences in mean serum TAG and Administration of GA improved LPL expression in liver, kidney, heart and adipose tissues in adrenalectomised rats
Comparing the sham and the ADX groups, LPL expression was not significantly down-regulated in the liver (-1.02 ± 0.60 fold), kidney (-1.06 ± 0.57 fold) and heart (-2.00 ± 0.24 fold) (p > 0.05). On the other hand, a non-significant up-regulation of LPL expression was seen in the AM (1.34 ± 0.52 fold), QF (1.98 ± 2.56 fold), SAT (1.05 ± 0.93 fold) and VAT (1.17 ± 1.73 fold) between the sham and the ADX groups (p > 0.05). However, the reverse was observed in the ADX rats administered with 100 mg/kg of GA. LPL expression in the ADX and the GA-administered ADX groups was increased in the liver (2.77 ± 1.40 fold), kidney (1.53 ± 0.65 fold), heart (1.22 ± 0.77), SAT (2.87 ± 2.20 fold ) and VAT (1.08 ± 1.29 fold). However, the increases were not significant in all these tissues (p > 0.05) except for the liver (p < 0.05). LPL expression was down-regulated in the AM (-1.45 ± 0.38 fold) and QF (-1.69 ± 0.65 fold), both of which exhibited no significant difference between the ADX and the GAadministered ADX groups (p > 0.05) (Figure 8 ) 
Administration of GA to adrenalectomised rats did not improved lipid deposition in all tissues except in the liver
In the liver, the mean lipid deposition was the highest in the ADX group (687.92 ± 124.69 AU), followed by the sham (594.50 ± 119.17 AU) and the GAadministered ADX (432.90 ± 68.54 AU) groups. Lipid deposition in the liver showed a significant decrease of 37.1% between the GA-administered ADX and the ADX groups (p < 0.05). In the kidney, the lipid deposition was observed to be 320. 35 
Administration of GA reduced size of adipocytes in adrenalectomised rats
Mean area of both SAT and VAT adipocytes showed significant decrease in the GA-administered group compared to both the sham and the ADX groups (p < 0.01) (Figure 10 ). 
DISCUSSION
The present study focuses on the effect of GA on glucose and lipid metabolism in adrenalectomised rats. When a rat is adrenalectomised, both the steroid secreting cortex and the catecholamine secreting medulla will be removed [34] . GA has been shown to inhibit 11β-HSD1 activities in tissues that led to reduction in active GCs level, thus improving insulin sensitivity [24] . Hence removing known action of GA on glucose and lipid metabolism involving endogenous steroids will allow us to determine the effects of GA on LPL expression and PEPCK, G6Pase and H6PDH activities in relation to glucose and lipid levels in the absence of adrenal glands. It also enables a better understanding on the possible mode of action of GA apart from its effect in the presence of endogenous steroids. In the present study, dietary sodium via the administration of saline was given to all the rats. Saline is essential for ADX and GA-administered rats as it is able to replace the acute sodium loss in ADX animals upon adrenalectomy, thus delaying or preventing the appearance of adrenalectomy-induced alterations that might lead to any lethal effect [34] . The sham group was also given saline to ensure that the only variables existing in the study is the lack of adrenal glands and the GA-administration.
The measurement of systolic blood pressure was carried out to investigate the possible side effects of GA consumption, which had been reported to be associated with hypermineralocorticoid-like effects [35] . In the present study, a non-significant fall in blood pressure was observed in the ADX group compared to the sham group. Mineralocorticoids are best known in modulating ion and water movement across the transport epithelial. Aldosterone (example of mineralocorticoid) is known to act on the nuclear mineralocorticoid receptors (MR) within the distal tubules and collecting ducts of the nephron, resulting in the sodium and water retention, potassium excretion, ultimately leading to increased blood pressure [36] . In adrenalectomised rats, the production of mineralocorticoid is halted due to the removal of adrenal glands, thus a fall in blood pressure is expected in the ADX rats. This observation is in agreement with a study by Dailey and Battarbee [34] where no significant fall in blood pressure was observed in ADX animals that had saline as their only drinking solution. No significant change in blood pressure was observed in the GA-administered ADX rats compared to the ADX rats. Tanahashi et al. [37] reported that prolonged consumption of GA resulted in hypernatreamia, hypokalaemia, hypertension and suppression of the renin-angiotensin system as well as low aldosterone levels due to the competitive inhibition of GA on 11β-hydroxysteroid dehydrogenase 2 (11β-HSD2) involving interaction of mineralocorticoid receptor [38] . However, this was not observed in our study where the mineralocorticoid secreting organ (adrenal glands) had been removed from the rats. This is in agreement with a study by Stormer et al. [35] who reported that the hypermineralocorticosteriod effects following the consumption of GA did not seem to occur in patients or animals with severe adrenal insufficiency. This has been further supported by the determination of serum sodium and potassium levels carried out in our lab where no significant difference in serum sodium and potassium levels were observed between the ADX and the GA-administered ADX groups (Yong ST, unpublished observations).
Circulating glucose levels reflect a balance between glucose production by the liver and glucose uptake [39] . The occurrence of disorders such as MetS and T2DM are usually preceded by the presence of insulin resistance [40] . Insulin is responsible for the regulation of plasma glucose levels [41] . A state of decreased sensitivity of peripheral tissues towards insulinstimulated glucose uptake or production leading to compensatory hyperinsulinaemia to maintain homeostasis contributes towards insulin resistance [42] . Hallmark symptoms of the metabolic syndrome involve deviation from normal glucose metabolism, with elevated fasting glucose and insulin levels. Glucose homeostasis was reported to occur within two hours after the last carbohydrate consumption [43] . Therefore, all the rats were subjected to 12-hours fast in order to represent the hepatic output via glycogenolysis. In the present study, a significant reduction in blood glucose level was seen in the ADX rats compared to the sham rats. This could be due to the removal of GCs upon adrenalectomy. GC acts as a functional antagonist to insulin [44] . It plays an essential role in the regulation of blood glucose. Elevation of blood glucose could result from GC effects via (1) increased gluconeogenesis in the liver, (2) increased gluconeogenic substrate (amino acids and glycerol) by inducing proteolysis and lipolysis in the skeletal muscles and adipose tissues respectively, (3) decreased insulin secretion from the pancreatic β-cells and (4) decreased peripheral tissue glucose uptake [45] [46] . Removal of GC could lead to reduction of blood glucose as seen in the present study. Increased glucose uptake by peripheral tissues in the ADX rats could be another possible factor contributing to the reduced blood glucose compared to the sham rats. GC's inhibition of protein kinase B phosphorylation in the muscles and adipose tissues prevents the translocation of glucose transporter isotype 4 (GLUT4) to the plasma membrane thereby reducing glucose uptake [46] . Thus absence of GCs in the ADX rats could stimulate an increase in glucose uptake in the muscle and adipose tissues of ADX rats leading to the observed lower blood glucose. This was further confirmed by PAS staining performed on the liver, kidney, adipose tissues and muscles (Haque F, unpublished observations). In our present study, liver tissues stained with PAS stain showed depleted hepatic glycogen stores in the sham rats which could be due to a combination of glucagon induced glycogenolysis and glucagon inhibited glycogenesis (Haque F, unpublished observations). The ADX and the GA-administered ADX rats were found to have more glycogen stores compared to the sham rats. GCs and epinephrine have been implicated in stimulating the release of glucagon and thus the absence of both GC and epinephrine in the ADX and GA-administered ADX rats could account for the greater hepatic glycogen stores observed.
No significant difference in blood glucose level was observed in GA-administered ADX rats compared to the ADX group. GA is a potent inhibitor of 11β-HSD and its inhibition results in decreased circulating concentrations of GC [47] . Decreased GC reduces activities of the gluconeogenic enzymes (PEPCK and G6Pase). As similar blood glucose levels were observed in both the ADX and GA-administered ADX groups, GA may not have any direct effect on the gluconeogenic enzymes in the absence of adrenal glands. This further reinstates that the observed inhibitory effects of GA on the gluconeogenic enzymes by Chandramouli et al. [28] could be primarily due to its actions on 11β-HSD1. In our study, the ADX rats have a higher non-significant serum insulin levels compared to the sham rats. This could be due to the absence of circulating GCs. There is evidence that GCs are capable of inhibiting insulin secretion from the β-cells of the pancreas. Although this has been difficult to prove in vivo, Lambillotte et al. [48] had demonstrated rapid inhibition of glucose-induced insulin secretion upon administration of GC in vitro. No significant difference in insulin level was seen between the ADX and GA-administered ADX groups. GA does not have any documented effect on serum insulin levels and our present study further reinstate this. Insulin levels in the post-absorptive stage are principally governed by circulating blood glucose [49] . An initial low blood glucose level resulting from fasting in all three groups may be an alternative explanation for the nonsignificant changes in insulin levels observed between the three groups. The HOMA-IR is used to access insulin sensitivity with a higher value indicating a higher insulin resistance (lower insulin sensitivity) and vice versa [50] . A reduction in HOMA-IR was observed in the ADX group compared to the sham group, denoting higher insulin sensitivity in the ADX rats. Chavez et al. [20] demonstrated that adrenalectomy increased the insulin sensitivity in the ADX rats. The reduction of HOMA-IR seen in the present study could be due to the lowered glucose levels as HOMA-IR reflects the product of glucose output and insulin secretion [50] . On the other hand, no significant difference was observed in HOMA-IR between the ADX and the GA-administered ADX groups.
In the present study, significant reduction in hepatic and renal PEPCK activities were observed in the ADX group compared to the sham group. GCs and glucagon are involved in the transcriptional regulation of the PEPCK gene. Binding of GCs to the GRE in the PEPCK promoter triggers the formation of the transcription initiation complex and recruitment of coactivators which are critical for PEPCK transcription [46, 51] . Glucagon induces the expression of PEPCK through stimulation of PGC-1α [52] . The absence of circulating GCs therefore accounts for the lower PEPCK activities observed in the ADX rats. Absence of GCs would also reduce circulating glucagon concentrations and this could be another factor contributing to the reduced PEPCK activities observed in the ADX rats. Thus the decreased PEPCK activities observed may be attributed to reduced GC and glucagon induced-transcription of the PEPCK gene. Low hepatic and renal gluconeogenesis thus account for the reduced blood glucose observed in the ADX rats compared to the sham rats. No difference in the enzyme activities was observed between the GA-administered ADX and the ADX rats. Regulation of PEPCK is achieved at the transcriptional level by various transcriptional factors and there is no known posttranslational modification of the enzyme. Transcriptional modification of PEPCK is directly related to the enzyme activity [53] . The absence of significant difference in the GA-administered ADX rats suggests that GA might not be involved in modulating the activity of these transcription factors. The PEPCK activities of the ADX and GA-administered ADX groups correlated with the blood glucose levels as there was no significant difference between the two groups. Another observation was that renal PEPCK activities were higher than hepatic PEPCK activities in all the groups. Although the liver is responsible for both gluconeogenesis and glycogenolysis, the circulating blood glucose is contributed mainly through glycogenolysis in the post-absorptive stage. 75% of hepatic glucose output is through glycogenolysis until hepatic glycogen stores are depleted [49] . Renal gluconeogenesis contributes to only 20% of circulating blood glucose under normal conditions and becomes more significant in the post-absorptive stage where it contributes to 40% of glucose output [54] [55] . Thus the increased PEPCK activities observed in the kidneys may be due to the combination of reduced hepatic gluconeogenesis and increased renal gluconeogenesis. Although GCs stimulate hepatic and renal PEPCK activities, they are responsible for the inhibition of PEPCK activities in adipose tissues [56] . PPAR-γ is important for the transcription of PEPCK as mutation of the PPAR-γ binding site in the PEPCK gene abolished PEPCK expression in adipose tissues. GCs have been implicated in interfering with the binding of PPAR-γ to the PEPCK gene promoter thus inhibiting glyceroneogenesis in adipose tissues [57] . Reshef et al., [13] demonstrated that adrenalectomy increases the rate of glyceroneogenesis in adipose tissues but this was not observed in our study. PEPCK activities in adipose tissues have been found to positively co-regulate with BMI, body fat percentage, fasting TAG and total cholesterol levels in human studies [58] . The nonsignificant difference observed between the ADX and sham rats could be due to the effects of these constellations of factors on PEPCK activities. Administration of GA to the ADX rats however has led to the significant elevation of PEPCK activities in the adipose tissues. As the involvement of GCs in the adipose tissues had been eliminated through adrenalectomy, elevation of PEPCK activities as observed in the GA-administered ADX group could be due to the agonistic effect of GA on PPAR-γ in adipose tissues [24] .
Significant reduction in hepatic and renal G6Pase activities was seen between the ADX and the sham groups. GCs and glucagon are responsible for the upregulation of PGC-1α which subsequently stimulates G6Pase activities [59] [60] . Absence of circulating GCs and the subsequent lowered circulating glucagon in the ADX rats could therefore account for the lower G6Pase activities. Reduced gluconeogenesis from decreased G6Pase activities leads to decreased blood glucose levels in the ADX rats. No significant difference was observed in the hepatic and renal G6Pase activities between the ADX and GA-administered ADX groups. The promoter region and the transcriptional factors involved in the regulation of G6Pase are similar to that of PEPCK [61] . Thus the effect of GA on the transcriptional factors involved in the regulation of G6Pase might be similar to that observed for the PEPCK enzyme. GA did not affect hepatic and renal G6Pase activities and this also correlated with the blood glucose levels in both the ADX and GAadministered ADX rats.
As aforementioned, H6PDH activities are modulated by 11β-HSD1 and G6P availability. Lavery et al. [64] highlighted the obligate relationship between H6PDH and 11β-HSD1. 11β-HSD1 oxo-reductase activities are observed in the ER under normal circumstances when NADPH is provided by H6PDH. H6PDH knock-out mice demonstrated minimal oxo-reductase activities and moderate dehydrogenase activities [27, 62] . G6P concentrations in the ER lumen are crucial in determining the set point of 11β-HSD 1 oxo-reductase activities [63] . Banhegyi et al. [27] demonstrated that addition of G6P increased production of NADPH in the ER and subsequently stimulated 11β-HSD1 activities. Inhibition of G6PT compromises G6P uptake into the ER and results in a subsequent decrease in 11β-HSD1 activities [27] . This further demonstrated the close functional cooperation between 11β-HSD1 and H6PDH. A close relationship between 11β-HSD activities and their mRNA levels have been reported indicating that the enzyme is regulated primarily at the transcriptional level [64] . GCs have been found to upregulate 11β-HSD1 mRNA levels both in vivo and in vitro [65] . Decreased H6PDH activities were observed in the ADX rats compared to the sham rats in all six tissues. Absence of circulating GCs would indirectly affect H6PDH activities through reduced up-regulation of 11β-HSD1 mRNA. This was further shown in the present study where decreased 11β-HSD1 enzyme activities were observed in the ADX groups with reference to the sham groups. Limited G6P availability might be another possible explanation for the reduced H6PDH activities observed in the ADX rats. Absence of circulating GCs would decrease stimulation of PEPCK and G6Pase and this would result in limited availability of G6P. As aforementioned, H6PDH activities are regulated by 11β-HSD1, Whorwood et al. [66] demonstrated that GA is capable of inhibiting the synthesis of 11β-HSD mRNA both in vitro and in vivo. Our present study is also in concordance to this where reductions of tissues 11β-HSD1 activities were seen in GA-administered ADX groups. GA's inhibitory actions on the synthesis of 11β-HSD1 mRNA might have resulted in the significantly lower H6PDH activities in the GA-administered ADX rats compared to the ADX rats. The non-significant changes in blood glucose in the ADX and ADX-GA treated rats correlate with the H6PDH activities in these two groups. H6PDH is not directly linked to the gluconeogenic pathway and GA's inhibition of 11β-HSD1 might not significantly impact the circulating GCs concentration due to the absence of GCs in both ADX and GA-administered ADX groups.
The TAG concentration measured after a fasting period of 12 hours in the present study represented the VLDL fraction instead of chylomicrons as the latter have a half-life of 15 to 20 minutes [43] . In dyslipidaemic individuals, high TAG concentration is attributed to the delayed lipolysis of both chylomicrons and VLDL following the down-regulation of LPL expression [7] . The present study showed no significant changes in the serum TAG levels of the ADX rats compared to the sham rats. However, there is an increasing trend seen in serum TAG and FFA levels in the ADX group compared to the sham group. This could be due to the insulin-induced hypoglycaemic effect seen in the ADX rats. In the absence of adrenaline, insulin-induced hypoglycaemia could be a potent stimulus for sympathetic nervous activation, thus triggering an increase in noradrenaline release [67] . Noradrenaline has potent lipolytic (breakdown of lipid) actions, particularly in the visceral fat depots, thus releasing FFAs as a source of energy, especially in a caloric deficit situation [68] . Lower LPL expression seen in the liver, kidney and heart in the ADX rats could have contributed to the increased FFA levels as well. The SAT of the ADX rats displayed a decrease in adipocytes size. Such decrease could be attributed to increased LPL expression seen in the SAT compared to that of the sham rats. This may indicate fat storage in the VAT. In an energy deficit condition, as seen in ADX rats, insulin would on the other hand limit the mobilisation of TAG from adipose tissue to maintain lipid store for later usage as well as inhibit the hepatic formation of VLDL cholesterol [69] , thereby resulting in lower total cholesterol levels seen in the ADX rats. As a result, the size of adipocytes in the VAT increased despite the increased LPL expression. Compared to the sham rats, increased LPL expression was observed in the SAT and VAT of the ADX rats. No direct correlation between the GC and the LPL expression has been reported except for the adipose tissues. GC has been reported to increase lipolysis in peripheral fat depots by inducing hormone-sensitive lipase and reduce LPL activities [46] . GCs also promote preadipocyte differentiation, pro-lipogenic pathway activity and cellular hypertrophy in central fat as well as decreases thermogenesis and uncoupling protein 1 expression in brown adipose tissue [70] . Hence, in the absence of GC upon adrenalectomy, low lipolysis would be seen through a reduction in hormonesensitive lipase activities and elevation of LPL activities.
Oral administration of 100mg/kg GA to the ADX rats resulted in increased LPL expression in the adipose tissues. In the VAT, significant reduction in the size of adipocytes was seen with H&E staining. This could be due to activation of PPAR-γ which causes the mature, lipid-filled adipocytes to undergo apoptosis [71] thereby leading to release of FFA from the hypertrophied adipocytes [72] . The results of the current study suggested that administration of GA might have activated the PPAR-γ expression in the VAT and caused the apoptosis of the mature adipocytes and probably had redeposited the fats in the SAT. This is further seen by a higher fold-difference in the upregulation of LPL expression in the SAT than in the VAT. The increase in LPL-mediated FFA uptake is higher in the SAT than the VAT, suggestive of diversion of most of the lipid to the subcutaneous depot. Besides that, the apoptotic process would induce the stimulation of adipogenesis from pre-adipocyte precursor cells, thus increasing the number of smaller and more insulin sensitive adipocytes in the SAT [73] . The subcutaneous depot may also act as a centre, with the capability to accommodate excess TAG [74] and may probably re-transport the fats to be excreted out from the body. Berthiaume et al. [75] and Bogacka et al. [76] reported that PPAR-γ-triggered adipocyte differentiation occurs predominantly in the SAT rather than VAT, thus favouring a diversion of lipid from the VAT to the SAT. This would lead to increased size of SAT and a decreased or unchanged size in VAT [77, 78] . The result of the present study is also in concordance to those reported by Eu et al. [23] , where the SAT adipocyte recorded an increase in size whereas the size of VAT adipocyte was reduced upon GAadministration to ADX rats. This suggested that GA might have also acted directly as a PPAR-γ ligand and causes the elevation of LPL expression independent of the involvement of GCs. The LPL expression in the liver was significantly up-regulated in the GAadministered ADX rats. The ORO-stained liver tissues showed a reduction in lipid deposition in the GAadministered ADX group compared to the ADX group. TAG is present in all cell types and intracellular storage of these neutral lipids occurs within lipid droplets. With the significant increase in the liver LPL expression and a reduction in lipid accumulation in the liver, it is suggested that the elevated LPL expression in the liver was to channel away the excess TAG, probably broken down and excreted. Induced LPL expression may help in the clearance of TAG-rich lipoprotein that led to the observed reduction in serum TAG concentration [77] . Increased LPL activities are associated with decreased plasma TAG levels, higher HDL cholesterol and reduced risk of coronary artery disease [78] . The upregulation of LPL expression in the liver may help in the improvement of the serum lipid parameters in the GA-administered ADX group relative to the ADX group. GA-administered ADX group showed a reduction in serum FFA, TAG, total cholesterol and LDL-cholesterol, accompanied by an elevation in HDL-cholesterol. Elevated HDL-cholesterol following GA administration to the ADX rats may be due to the increased production of apo A-I, the major protein of HDL that is subjected to accelerated catabolism in the MetS [79] . Apo A-I mRNA has been shown to be elevated in 11β-HSD1 knock-out mice [80] and following PPAR-α activation [81] . Assuming the role of 11β-HSD1 in inhibiting apo A-I has been excluded via the adrenalectomy, the increased production of apo A-I may then be from the GA probably by the activation of PPAR-α. These further suggest that GA administration may lead to activation of PPAR-α thereby increasing apo A-I and HDL synthesis. Muscle LPL over-expression has been demonstrated to result in increased intra-tissue TAG content and such increased lipid deposition in peripheral tissues have been linked to impairment of insulin signalling and IR [82] . Our present study on GA-administered ADX rats however, showed a down-regulation of LPL expression in the AM and QF. The decreased LPL expression in muscles may represent an attempt to limit the TAG accumulation in the muscles [83] . This is in accordance with the ORO-staining performed where less lipid accumulation was observed in both the AM and QF in GA-administered ADX group. Such alteration in muscle LPL expression could probably be the consequence of the integrated adaptation by the ADX rats in response to the GA-induced TAG redistribution seen in other peripheral tissues, aiming to drive the lipids toward adipose storage sites and limiting their uptake by TAG-laden muscles [83] . Increased lipid deposition was observed in the kidneys and the heart of the GA-administered ADX rats. However, upregulation of LPL expression was seen in both the kidneys and heart of the GA-administered ADX rats. LPL is an important enzyme in cardiac lipid uptake and metabolism [84] and increased expression levels in both the tissues was postulated for the removal of excess fat away from the organs. It has been shown that heart-specific LPL knockout mice display elevated plasma TAG levels and decreased clearance of postprandial lipids despite normal post-heparin plasma LPL activity [85] . Increased cardiac glucose metabolism and cardiac dysfunction have also been observed in these mice [86] . Besides, increased circulating fats around the heart could lead to atherosclerosis or even coronary heart disease [87] . Therefore, GA-induced increased expression of LPL in the heart might exert a cardioprotective effect on the heart from the circulating TAG. The increased LPL expression in the heart could be due to the increased activation of PPARs on the PPRE as LPL gene was found downstream of the transcriptionally active PPRE [5] . As PPAR-α is highly expressed in the heart [88] , it could therefore suggest that GA may act as a PPAR-α ligand that results in the increased heart LPL expression seen in the GA-administered ADX rats. Similarly in the kidneys, GA-induced increase in LPL expression could be due to PPAR-γ activation due to its expression and role in the kidney [88] . Increased LPL expression in the kidney could function by hydrolysing the circulating TAG around the kidneys to exert renoprotective effects, preventing the development of nephropathy. Consequences of excess kidney lipid deposition have been reported to be associated with hypertension [89] as well as important modulators of progressive renal disease [90] . However, no changes in blood pressure and serum electrolytes concentration (Na + /K + ) were observed between the GA-administered ADX and the ADX groups, indicating functions of the kidneys may not be impaired in the present study (Yong ST, unpublished observations). Taking into consideration the overall effect of GA, it has been shown that increased LPL expression might have assisted in lowering the circulating FFA and TAG. However, increased LPL expression did not result in increased lipid deposition. This may be due to GA activating PPAR-α thus increasing β-oxidation and these are independent of GC.
In conclusion, the present study showed that blood glucose level was reduced significantly in ADX rats compared to the sham rats but GA administration to ADX rats did not improve glucose level. Significant reduction observed in hepatic and renal PEPCK and G6Pase activities between the ADX and sham rats absent in the GA-administered rats showed that GA has no effect on these enzymes, demonstrating that GC is responsible for the two enzymes activities in the liver and kidney. Increased adipose tissues PEPCK activities in GA-administered ADX rats on the other hand suggest that GA's action on these enzymes were independent of GC. Significant reduction of H6PDH activities were observed in all tissues in the ADX rats compared to the sham rats and further reductions were observed in all the aforementioned tissues except the adipose tissues in the GA-administered ADX rats. These findings further suggest the possible role of GA on reduction of tissues H6PDH apart from its effects on GC. Increased LPL expression in the skeletal muscles and adipose tissues of the ADX rats compared to the sham rats may suggest the involvement of GC on these. However, increased LPL expressions were seen in the liver, kidney, heart and adipose tissues of the GAadministered ADX compared to the ADX rats. GA administration to ADX rats also led to improvement in total cholesterol, HDL-and LDL-cholesterol levels. These may be due to the effects of GA on the upregulation of tissue LPL expression either directly or probably through PPAR-α and PPAR-γ activation, independent of GC.
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